Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
Uncategorised
Nippon India Pharma Fund-Growth Plan-Growth Option
Nippon India Mutual Fund · Managed by Sailesh Raj Bhan; Kinjal Desai; Amber Singhania
32slipping
Latest NAV
₹571.0216
as of 07 Aug 2026
AUM
—
Expense ratio
—
Inception
14 May 2026
FundScore
32/100slipping
Rank #680 of 1007 · top 68%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
2.80%
3M
6.17%
6M
15.09%
1Y
12.78%
3Y CAGR
17.56%
5Y CAGR
12.74%
Since incep.
17.71%
Fund details
- Fund manager
- Sailesh Raj Bhan; Kinjal Desai; Amber Singhania
- Riskometer
- Very High Risk
- Type
- Open Ended
- Portfolio turnover
- 16%
- Volatility (3Y)
- 15.4%
- Rating (external)
- —
Investment objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap41.0%
Mid cap29.3%
Small cap29.6%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 31 May 2026.
Sun Pharmaceutical Industries Limited
equity
13.35%
Lupin Limited
equity
7.31%
Dr. Reddy's Laboratories Limited
equity
6.72%
Cipla Limited
equity
6.16%
Divi's Laboratories Limited
equity
5.80%
Apollo Hospitals Enterprise Limited
equity
5.20%
Mankind Pharma Limited
equity
3.94%
MedPlus Health Services Limited
equity
3.68%
Sai Life Sciences Limited
equity
3.43%
Vijaya Diagnostic Centre Limited
equity
3.21%
Ajanta Pharma Limited
equity
3.21%
Max Healthcare Institute Limited
equity
2.97%
Thyrocare Technologies Limited
equity
2.56%
IPCA Laboratories Limited
equity
2.41%
GlaxoSmithKline Pharmaceuticals Limited
equity
2.34%
Aurobindo Pharma Limited
equity
2.32%
Abbott India Limited
equity
2.31%
Gland Pharma Limited
equity
2.09%
Alkem Laboratories Limited
equity
2.06%
Dr. Lal Path Labs Limited
equity
1.90%
Narayana Hrudayalaya Limited
equity
1.81%
Syngene International Limited
equity
1.79%
Pfizer Limited
equity
1.69%
Emcure Pharmaceuticals Limited
equity
1.47%
Suraksha Diagnostic Limited
equity
1.29%
Fortis Healthcare Limited
equity
1.19%
Sanofi Consumer Healthcare India Limited
equity
1.14%
Anthem Biosciences Limited
equity
0.93%
Akums Drugs and Pharmaceuticals Limited
equity
0.92%
Sanofi India Limited
equity
0.83%